Modeling population benefit versus individual risk (benefit-risk assessments) for the tetravalent live attenuated dengue vaccine developed by Takeda (TAK-003)

WHO
Modeling population benefit versus individual risk (benefit-risk assessments) for the tetravalent live attenuated dengue vaccine developed by Takeda (TAK-003) Request for proposal

Reference: 2023.1-UHL-IVB_SAGE
Beneficiary countries: Multiple destinations (see 'Countries' tab below)
Registration level: Basic
Published on: 09-Mar-2023
Deadline on: 31-Mar-2023 23:59 (GMT 1.00)

Description

The purpose of this Request for Proposals is to identify a suitable contractor to carry out  modelling of dengue vaccination scenarios to address one or more of the questions specified in Appendix 1 , the anticipated deliverables of the work include:

  • Methodology document providing scenarios, key input parameter values and data sources;
  • Presentation slide decks with preliminary and final model results and conference calls with the WHO SAGE Working Group on Dengue Vaccines and WHO Immunization, Vaccines, and Biologicals Department staff (Value of Vaccination, Modeling, and Economics Team) to receive feedback on methodology and results;
  • Pre-print or other report format posted on a publicly accessible website reporting the final model results.

See detailed Terms of Reference and bidding instructions under “Documents” below. 


Please note: it is NOT necessary to click on “Express Interest” on the top right-hand side of the screen. In order to inform WHO that you are interested in participating in this Request for Proposals, please follow the provisions of the RFP document below.